---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-025061"
form_type: "8-K"
ticker: "ENSC"
cik: "0001716947"
company_name: "Ensysce Biosciences, Inc."
filed_at: "2026-05-22T20:55:24+00:00"
generated_at: "2026-05-22T20:58:03.305562+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Nasdaq notifies Ensysce of delisting risk for equity shortfall

## Summary
- Received Nasdaq notice on May 21, 2026 for non-compliance with $2.5M stockholders' equity requirement as of March 31, 2026.
- Must submit a plan by July 6, 2026 (45 days) to regain compliance; if accepted, extension up to 180 days from May 21.
- Company plans to submit a timely plan and explore options, but no assurance Nasdaq will accept or extension granted.
- Failure could lead to delisting; company may appeal to Nasdaq Hearings Panel if plan rejected.

## SEC filing metadata
- accession: 0001493152-26-025061
- form_type: 8-K
- ticker: ENSC
- cik: 0001716947
- company_name: Ensysce Biosciences, Inc.
- filed_at: 2026-05-22T20:55:24+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.85
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716947/000149315226025061/0001493152-26-025061-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716947/000149315226025061/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-025061
- JSON: https://secwatch.observer/filing/0001493152-26-025061.json
- Plain text: https://secwatch.observer/filing/0001493152-26-025061.txt

## Source-grounded claims
- claim_id: 0e91685b29e13c8ef1e7ef543f0e47eb6853323c
  claim: Ensysce Biosciences, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
  evidence_excerpt: On May 21, 2026, Ensysce Biosciences Inc. (the “ Company ”) received notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) stating that due to the Company’s non-compliance with the $2.5 million stockholders’ equity requirement set forth in Nasdaq Listing Rule 5550(b)(1) as of March 31, 2026, the Company is subject to delisting
  evidence_url: https://www.sec.gov/Archives/edgar/data/1716947/000149315226025061/0001493152-26-025061-index.htm
- claim_id: 27087ce2350d9925d45f509f7b4401f26ea73cd9
  claim: Ensysce Biosciences, Inc. received a nasdaq other notice regarding stockholders equity (rules 5550(b)(1)).
  evidence_excerpt: If the plan is accepted, the Company may be granted an extension of up to 180 days from May 21, 2026, to regain compliance.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1716947/000149315226025061/0001493152-26-025061-index.htm
- claim_id: 5b8e9c59912ead1eb2b2aa24de4487549bcd80be
  claim: Ensysce Biosciences, Inc. received a nasdaq hearing update notice regarding stockholders equity (rules 5550(b)(1)).
  evidence_excerpt: If the plan is not accepted, the Company may appeal to the Nasdaq Hearings Panel (the “Panel”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1716947/000149315226025061/0001493152-26-025061-index.htm
- claim_id: 7c00c28a878d949f315bb80553f1443ac1392b28
  claim: Ensysce Biosciences, Inc. received a nasdaq noncompliance notice notice regarding stockholders equity (rules 5550(b)(1)).
  evidence_excerpt: unless it submits a plan within 45 days (by July 6, 2026) to regain compliance.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1716947/000149315226025061/0001493152-26-025061-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.